Back
Issues Notice in Case Against Over Online Drug Sales
The has officially issued notice in the filed by the State of Karnataka concerning the alleged unauthorized sale of pharmaceutical products on the online marketplace platform, . The matter, which involves complex questions regarding for the sale of , was heard by a bench comprising Hon’ble Mr. Justice Ahsanuddin Amanullah and Hon’ble Mr. Justice R. Mahadevan.
Genesis of the Dispute
The legal proceedings originated following an online transaction conducted via the portal, where an order was placed for "Suhagra-100" tablets. The local prosecution, as initiated by a drugs inspector, alleged that the third-party seller, , operated without a valid license to distribute such pharmaceutical products. Furthermore, it was asserted that the medicine, which falls under , was supplied to the consumer without the mandatory requirement of a doctor’s prescription.
Following this, a was filed before the . The magistrate subsequently took of the claims, leading to the issuance of against and its directors.
The Legal Crossroads
The primary legal question centers on the extent of governance over e-commerce intermediaries when third-party vendors host and sell regulated medicinal products. The State of Karnataka, through this petition, seeks to challenge the 's earlier decision, which had implications for the prosecution of these corporate entities under the .
The Bench, having considered arguments from both sides during the morning and afternoon sessions, decided to link this case with a pending matter, , to ensure consistency in the adjudication of these issues.
Key Observations
During the course of the proceedings, the Bench emphasized the need for a comprehensive hearing on the merits:
-
"Issue notice both on the as well as on the application seeking ."
-
"The matter has been taken up and heard in view of the order passed... along with ."
-
"List on at 02:00 p.m. along with ."
Judicial Outlook
By opting to list this matter alongside an identical pending case, the Supreme Court has signaled a methodical approach to evaluating the regulatory scope of the Drugs and Cosmetics Act in the digital age. The upcoming hearing on August 10, 2026, is expected to provide much-needed clarity on the intersection between e-commerce platform operations and the rigorous standards required for the sale of medical drugs in India. The Court's decision to issue notice ensures that respondents must now address the specific allegations of procedural and violations before the Apex Court.
